Organization · Venture Capital
Northislet
Northislet AB is a growth capital investor based in Stockholm, Sweden, specializing in life science and healthcare investments in the Nordic region. The firm focuses on enhancing the long-term value of small growth-stage companies through active ownership strategies.
Overview
What Northislet does
What Northislet is
Northislet AB is a growth capital investor based in Stockholm, Sweden, specializing in life science and healthcare investments in the Nordic region. The firm focuses on enhancing the long-term value of small growth-stage companies through active ownership strategies.
How it participates in the startup ecosystem
The current public profile supports funder capabilities. Each capability below is shown separately so organization identity and role-specific information do not get conflated.
Operational profile
Organization status and context
Organization status describes the entity itself. Funding and program availability appear within the relevant capability profile.
- Operational status
- Active
- Organization type
- Venture Capital
- Founded
- Founded in 2017
- Approximate age
- About 9 years
- Structured capabilities
- Funder
- Last reviewed
- April 22, 2026
Official channels
Find Northislet elsewhere
Open the official website or a supported primary organization account.
Capability profile
Northislet as a funder
Investment thesis
Northislet focuses on long-term active ownership of small-cap Nordic life science companies, diversifying early-stage investments while consolidating and holding successful ventures.
Focus narrative
Northislet invests in small and mid-sized growth companies at various stages within the life science and healthcare sectors. The organization prioritizes businesses that provide essential tools for the pharmaceutical and life science industries, adopting a long-term investment approach without defined exit timelines. Northislet supports both listed and unlisted companies throughout their life cycles.
Value beyond capital
Northislet adds value through active ownership, leveraging its expertise to support portfolio companies in achieving long-term growth and sustainability. The firm emphasizes a collaborative approach with entrepreneurs and management teams to enhance operational efficiencies and strategic direction.
Focus and fit
- Stages
- Seed · Series A · Series B · Growth Equity
- Regions
- Nordics
Availability
- Currently deploying
- Yes
Portfolio and track record
- Recorded portfolio count
- 5
Portfolio context
Notable portfolio companies include: Akiram Therapeutics: Focuses on advancing radiotherapeutics to treat solid tumors. Elypta: Works on advancing cancer detection technologies. Neogap: Develops personalized cancer therapies that enhance tumor-specific immune responses. Saga Diagnostics: Specializes in ultrasensitive cancer diagnostics and monitoring. Spago Nanomedical: Engages in precision nanomedicine for improved diagnosis and treatment.
Common questions
What to know about Northislet
Upseed classifies Northislet under the Venture Capital organization type. Its current public profile includes funder capabilities.
Source and update disclosure
Know what this page is based on
Source basis
Public organization and program material, official websites, and structured Upseed records.
Last reviewed
April 22, 2026
Known limits
Capability profiles appear only when a structured public profile also contains decision-useful role evidence. Terms and availability can change.
Upseed is an independent guide. It is not affiliated with or endorsed by the organization described on this page.